Nektar Therapeutics

5 days ago · defenseworld.net

Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Profitability This table compares Evaxion A/S and Nektar

28 days ago · prnewswire.com

REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w First large, placebo-controlled trial to support T-reg modulation as a clinical mechanism for immunoregulation of chronic inflammatory disease Findings support the continued development of rezpegaldesleukin in the ongoing Phase 3 ZENITH AD clinical program SAN FRANCISCO, Aug. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of peer-reviewed data from the 16-week induction period of REZOLVE-AD, a global, randomized, double-blind, placebo-controlled Phase 2b study evaluating rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis (AD). The publication in The Lancet, a world-leading medical journal, provides the medical and scientific community with the full reporting of efficacy, safety, pharmacodynamics, pharmacokinetics, and biomarker findings from the 16-week induction period of the Phase 2b trial.

1 month ago · seekingalpha.com

Nektar Therapeutics maintains a Strong Buy rating, driven by REZPEG's late-stage development in atopic dermatitis [AD] and alopecia areata [AA]. The Phase 3 ZENITH AD program is underway, with three pivotal studies targeting moderate-to-severe AD subpopulations; topline data is expected mid-2028. REZPEG's differentiated mechanism aims for long-term disease control and safety advantages over current AD therapies, addressing a $37.3B global market.

1 month ago · zacks.com

NKTR's Q2 earnings beat estimates, but revenues fall short. Investor focus stays on rezpeg as late-stage studies advance in autoimmune diseases.

1 month ago · seekingalpha.com

Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript

1 month ago · marketbeat.com

Nektar Therapeutics NASDAQ: NKTR said it initiated its global Phase III ZENITH AD program for rezpegaldesleukin, or REZPEG, in moderate-to-severe atopic dermatitis during July, while also finalizing plans for a registrational Phase III trial in alopecia areata following an end-of-Phase II meeting with the U.S. Food and Drug Administration.

1 month ago · zacks.com

Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $2.06. This compares to a loss of $2.78 per share a year ago.

1 month ago · prnewswire.com

SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial results for the second quarter ended June 30, 2026. Cash and investments in marketable securities on June 30, 2026, were $1,023.4 million as compared to $245.8 million on December 31, 2025.

1 month ago · prnewswire.com

NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Nektar Therapeutics misrepresented or failed to disclose that: (1) enrollment in its REZOLVE-AA trial for its lead product candidate had not followed applicable instructions and protocol standards; (2) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial's results; (3) accordingly, the REZOLVE-AA trial's overall integrity and prospects were overstated; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

1 month ago · defenseworld.net

Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) will likely be releasing its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Nektar Therapeutics to post earnings of ($1.97) per share and revenue of $10.4250 million for the quarter. Investors may review the information on the company's upcoming Q2 2026 earning overview